Epstein AL - Search Results

1

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: epstein al. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

2

Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.

Li J, Hu P, Khawli LA, Epstein AL. Li J, et al. Among authors: epstein al. Cancer Res. 2003 Dec 1;63(23):8384-92. Cancer Res. 2003. PMID: 14679000

3

A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.

Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL. Hu P, et al. Among authors: epstein al. Cancer Res. 1996 Nov 1;56(21):4998-5004. Cancer Res. 1996. PMID: 8895756

4

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.

Liu A, Hu P, Khawli LA, Epstein AL. Liu A, et al. Among authors: epstein al. Clin Cancer Res. 2005 Dec 1;11(23):8492-502. doi: 10.1158/1078-0432.CCR-05-1411. Clin Cancer Res. 2005. PMID: 16322313

5

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.

Zhang N, Khawli LA, Hu P, Epstein AL. Zhang N, et al. Among authors: epstein al. Clin Cancer Res. 2005 Aug 15;11(16):5971-80. doi: 10.1158/1078-0432.CCR-05-0554. Clin Cancer Res. 2005. PMID: 16115941

6

Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors.

Zhang N, Khawli LA, Hu P, Epstein AL. Zhang N, et al. Among authors: epstein al. Cancer Biother Radiopharm. 2007 Jun;22(3):342-56. doi: 10.1089/cbr.2007.359.A. Cancer Biother Radiopharm. 2007. PMID: 17651040

7

Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.

Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Hu P, et al. Among authors: epstein al. Cancer Res. 2003 Aug 15;63(16):5046-53. Cancer Res. 2003. PMID: 12941833

8

Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.

Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL. Hornick JL, et al. Among authors: epstein al. Blood. 1997 Jun 15;89(12):4437-47. Blood. 1997. PMID: 9192768 Free article.

9

NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.

Khawli LA, Hu P, Epstein AL. Khawli LA, et al. Among authors: epstein al. Clin Cancer Res. 2005 Apr 15;11(8):3084-93. doi: 10.1158/1078-0432.CCR-04-2310. Clin Cancer Res. 2005. PMID: 15837764

10

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. Pardee AD, et al. Among authors: epstein al. Cancer Res. 2010 Nov 15;70(22):9041-52. doi: 10.1158/0008-5472.CAN-10-1369. Epub 2010 Nov 2. Cancer Res. 2010. PMID: 21045144 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters